Sector: Healthcare | Industry: Pharmaceuticals |
Company Contact | |
Address: | 151 John Street BARRIE ON L4N 2L1 |
Tel: | N/A |
Website: | https://www.medipharmlabs.com |
IR: | See website |
Key People | ||
Keith Strachan President | David Pidduck Chief Executive Officer, Director | Greg Hunter Chief Financial Officer |
Business Overview |
MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. The Company's subsidiary, Harvest Medicine provides clinic services to Canadian patients requiring medical cannabis education and prescriptions. |
Financial Overview |
For the three months ended 31 March 2024, Medipharm Labs Corp revenues increased 67% to C$9.8M. Net loss increased 17% to C$3.6M. Revenues reflect Products transferred at a point in time segment increase of 57% to C$8.8M, Products and services transferred over time segment increase from C$247K to C$962K, Canada segment increase of 64% to C$6.5M, Australia segment increase from C$51K to C$1.8M. |
Employees: | 166 as of Dec 31, 2023 |
Reporting Currency: | Canadian Dollars |
Enterprise value: | $16.63M as of Mar 31, 2024 |
Annual revenue (TTM): | $36.99M as of Mar 31, 2024 |
EBITDA (TTM): | -$17.71M as of Mar 31, 2024 |
Net annual income (TTM): | -$13.61M as of Mar 31, 2024 |
Free cash flow (TTM): | -$11.28M as of Mar 31, 2024 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 404,175,883 as of May 15, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |